IRW-News: Medigene AG: Medigene AG: Scientific paper on the co-receptor-independent MAGE-A4-specific T-cell receptor |  03/30/21

IRW-News: Medigene AG: Medigene AG: Scientific paper on the co-receptor-independent MAGE-A4-specific T-cell receptor | 03/30/21

IRW-News: Medigene AG: Medigene AG: Scientific paper on the co-receptor-independent MAGE-A4-specific T-cell receptor |  03/30/21

IRW-PRESS: Medigene AG: Medigene AG: Scientific paper on the co-receptor-independent MAGE-A4-specific T-cell receptor

Peer-reviewed Publikation im Journal for Immunotherapy of Cancer

Planegg / Martinsried (March 30, 2021) – March 30, 2021. Medigene AG (Medigene, FWB: MDG1, Prime Standard), an immuno-oncology company with clinical projects focused on the development of T-cell-directed cancer therapies, announces the publication of a peer-reviewed publication in the Journal for Immunotherapy of Cancer with the title “Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy” (development of a CD8 co-receptor Receptor-independent T-cell receptor specific for the tumor-associated antigen MAGE-A4 for T-cell-based immunotherapies of the next generation), which is related to preclinical research on a T-cell receptor (T cell receptor, TCR ) specifically for a peptide derived from the MAGE-A4 protein. The research was carried out by Medigene scientists in collaboration with scientists from bluebird bio, Inc. (bluebird bio, NASDAQ: BLUE). The work was published online here: https://jitc.bmj.com/content/9/3/e002035

In the thesis the discovery and characterization of a MAGE-A4-specific TCR is described and detailed scientific information is shown, which highlights the efficiency and extraordinary specificity of this TCR against a peptide of the MAGE-A4 protein.

This MAGE-A4-specific TCR is the most advanced program from Medigene’s collaboration with bluebird bio. This TCR differs from other MAGE-A4 TCRs currently under development in that it works independently of the T cell co-receptor CD8, which is located on killer T cells. As shown in the work, this enables T cells equipped with this MAGE-A4 TCR to recognize and kill tumor cells that express MAGE-A4 in preclinical experiments. Helper T cells that express CD4 and not CD8 can also do this.

Prof. Dolores Schendel, CEO and Chief Scientific Officer at Medigene: “We are pleased that the high quality of our joint research with bluebird bio is recognized by this scientific publication. This MAGE-A4-specific TCR can, as it is independent of the CD8-Co Receptor is to activate MAGE-A4-specific responses in both CD4 helper and CD8 killer T cells. In this way, the TCR enables the broadest functional T cell response against MAGE-A4 positive tumor cells and, as shown in preclinical in vivo models, a strong control of tumor growth.

Our allogeneic T cell priming and selection technology has been used very successfully to isolate this TCR. This technology is well suited to find those non-mutant, high-avidity TCRs that are specific for different antigens and that we believe will be key to developing next-generation TCR T cells for solid tumors will.”

Scientific background

The MAGE-A4-specific HLA-A2-restricted TCR was isolated using Medigene’s allogeneic priming technology in order to stimulate T cells from an HLA-A2 negative donor and to screen for cells with the desired specificity. In preclinical research, the TCR has a favorable activity profile and superior in vivo potency compared to other specific MAGE-A4 TCRs tested (including those isolated from HLA-A2 positive donors who have a tolerated T-cell repertoire have self antigens presented by HLA-A2). This non-mutated, highly avid MAGE-A4-specific TCR is CD8 co-receptor-independent, so that effector functions can be triggered in CD4 helper T cells that have been transduced to express the TCR. These CD4 TCR-T cells not only support an anti-tumor response by directly killing MAGE-A4 positive tumor cells, but also upregulate certain properties such as the expression of surface markers and the release of key cytokines associated with helper function .

— End of press release —

About Medigene

Medigene AG (FWB: MDG1, Prime Standard, ISIN DE000A1X3W00,) is a listed biotechnology company with headquarters in Martinsried near Munich. The company develops highly innovative immunotherapies for the treatment of various types and stages of cancer. Medigene concentrates on personalized, T-cell-directed therapy approaches. Corresponding projects are in preclinical and clinical development.

Further information at www.medigene.de

About Medigenes TCR-Ts

TCR technology aims to equip the patient’s own T cells with tumor-specific T cell receptors (T cell receptors, TCRs). The T cells modified with regard to their receptor are thereby able to recognize tumor cells and to destroy them effectively. This immunotherapeutic approach attempts to overcome the existing tolerance to cancer cells and tumor-induced immunosuppression in the patient by activating and modifying the patient’s T cells outside the body (ex vivo).

Medigene is conducting a phase I / II clinical trial with its TCR-T candidate MDG1011 for the blood cancer indications AML and MDS. In addition, Medigene is building a pipeline of TCRs and is cooperating with bluebird bio, Inc. and Cytovant Sciences HK Ltd. with a focus on solid tumor indications.

This release contains certain forward-looking statements. These reflect the opinion of Medigene as of the date of this announcement. The results actually achieved by Medigene may differ materially from the statements made in the forward-looking statements. Medigene is not obliged to update forward-looking statements. Medigene® is a trademark of Medigene AG. This trademark may be owned or licensed for selected countries.

Contact

Dr. Gary Waanders, Dr. Anna Niedl

Tel.: +49 89 2000 3333 01

E-Mail: [email protected]

(End)

Sender: Medigene AG

Address: Lochhamer Straße 11, 82152 Planegg / Martinsried

Country Germany

Contact person: Medigene PR / IR

Tel.: +49 89 2000 3333 01

E-Mail: [email protected]

Website: www.medigene.de

ISIN(s): DE000A1X3W00 (Aktie)

Exchanges: Regulated Market in Frankfurt; Regulated Unofficial Market in Stuttgart, Regulated Unofficial Market in Munich, Regulated Unofficial Market in Hamburg, Regulated Unofficial Market in Düsseldorf, Regulated Unofficial Market in Hanover; Regulated Unofficial Market in Berlin, Tradegate

The original English report can be found under the following link:

https://www.irw-press.at/press_html.aspx?messageID=57580

The translated message can be found under the following link:

https://www.irw-press.at/press_html.aspx?messageID=57580&tr=1

NEWSLETTER REGISTRATION:

Current press releases of this company directly in your mailbox:

http://www.irw-press.com/alert_subscription.php?lang=de&isin=DE000A1X3W00

Announcement transmitted by IRW-Press.com. The broadcaster is responsible for the content.

Free reprinting permitted provided the source is acknowledged.

[ source link ]
https://www.finanzen.at/nachrichten/aktien/irw-news-medigene-ag-medigene-ag-wissenschaftliches-paper-ueber-den-co-rezeptor-unabhaengigen-mage-a4-spezifischen-t-zell-rezeptor-1030260858
IRWNews Medigene Medigene Scientific paper coreceptorindependent MAGEA4specific Tcell receptor

Leave a Reply

Your email address will not be published. Required fields are marked *